CGEN — Compugen Ltd.
$2.10
$-0.02 (-0.94%)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Market Cap
$198.92M
Forward P/E
-6.0x
52-Week Range
N/A
CGEN Price History
Revenue vs. Net Income
$72.8M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$31.3M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
23.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.9x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.4%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+4.8%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
